<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490203</url>
  </required_header>
  <id_info>
    <org_study_id>LIFE_ISS_2011</org_study_id>
    <nct_id>NCT01490203</nct_id>
  </id_info>
  <brief_title>Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma</brief_title>
  <acronym>LiFE</acronym>
  <official_title>Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the global and segmental hepatic uptake and&#xD;
      excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver&#xD;
      function test results in the patients with Hepatocellular Carcinoma (HCC) before major&#xD;
      hepatic resection or radiofrequency ablation (RFA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Preoperative/RFA assessment of remnant liver function is important for avoiding&#xD;
           posthepatectomy liver failure. However, the function of the future remnant is decreased&#xD;
           in patients with chronic liver disease or cirrhosis, compared to that of healthy&#xD;
           patients with an equal volume. Therefore, volume-based estimation of hepatic reserve&#xD;
           function is inadequate for patients with hepatic dysfunction.&#xD;
&#xD;
        2. Standard clinical liver function tests, such as ICG clearance rate or Child-Pugh score,&#xD;
           provides measurements of the global hepatic function, but cannot evaluate the functional&#xD;
           distribution in the liver. Gd-EOB-DTPA (Gadoxetic acid, PrimovistÂ®, Bayer Schering)&#xD;
           enhanced MRI has been recently demonstrated to have the potential to be an imaging-based&#xD;
           liver function test, with the possibility to detect functional differences on a regional&#xD;
           or even segmental level.&#xD;
&#xD;
        3. Gd-EOB-DTPA-enhanced liver MRI may be able to assess not only global but also segmental&#xD;
           liver function in patients with hepatocellular carcinoma (HCC) who have a relatively&#xD;
           high risk for developing liver failure after surgical resection due to coexistent&#xD;
           hepatic damage by chronic viral hepatitis and/or cirrhosis preoperatively.&#xD;
&#xD;
      The purpose of this study is to determine whether the global and segmental hepatic uptake and&#xD;
      excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver&#xD;
      function test results in the patients with HCC before major hepatic resection/RFA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results</measure>
    <time_frame>3 days (upto 5 days) after surgery</time_frame>
    <description>Predicted RLF (HEF mL) = the sum of the individual HEF of each voxel in future remnant segment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of various functional and volumetric parameters derived from Gd-EOB-DTPA enhanced MRI and clinical liver function tests obtained before and after surgical resection</measure>
    <time_frame>within 7 days before, and 3 to 5 days after surgery</time_frame>
    <description>Functional parameters derived from Gd-EOB-DTPA enhanced MRI include hepatic extraction fraction [HEF], input-relative blood flow [irBF], hepatocellular uptake index [HUI], liver to spleen ratio (LSR).&#xD;
Volumetric parameters include global liver volume and remnant liver volume.&#xD;
Clinical liver function tests include ICG R15, MELD score and Child-Pugh score.&#xD;
ICG R15 [Indocyanine green retention at 15 minutes, %] test will be performed within 3 days of preoperative MRI and 3 days after surgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical and MRI parameters of postoperative complication and morbidity</measure>
    <time_frame>upto 3 months (plus minus 1 week) after discharge</time_frame>
    <description>Clinical parameters refer to the following.&#xD;
Frequency of POD#5 days 50-50 criteria&#xD;
Evaluation of operation related complication&#xD;
Incidence of hepatic failure or death&#xD;
Functional and volumetric MRI parameters of patients with postoperative complication and morbidity will be evaluated.&#xD;
Correlation of MRI parameters with laboratory liver function tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors</measure>
    <time_frame>within 3 days of ICG R15 test</time_frame>
    <description>Correlation of functional parameters derived from Gd-EOB-DTPA enhanced MRI with ICG R15&#xD;
Correlation of functional and volumetric parameters derived from Gd-EOB-DTPA enhanced MRI&#xD;
Correlation of volumetric parameters derived from Gd-EOB-DTPA enhanced MRI and ICG15&#xD;
Comparison of functional MRI parameters between potential liver donors and patients undergoing hepatic resection for HCC.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">71</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group 1: HCC resection/RFA</arm_group_label>
    <description>Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Potential liver donor</arm_group_label>
    <description>Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gd-EOB-DTPA</intervention_name>
    <description>Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.&#xD;
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.</description>
    <arm_group_label>Group 1: HCC resection/RFA</arm_group_label>
    <other_name>Gadoxetic Acid Disodium</other_name>
    <other_name>Primovist/Eovist</other_name>
    <other_name>BAY86-4873</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gd-EOB-DTPA</intervention_name>
    <description>Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.&#xD;
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.</description>
    <arm_group_label>Group 2: Potential liver donor</arm_group_label>
    <other_name>Gadoxetic Acid Disodium</other_name>
    <other_name>Primovist/Eovist</other_name>
    <other_name>BAY86-4873</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.&#xD;
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.</description>
    <arm_group_label>Group 1: HCC resection/RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.&#xD;
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.</description>
    <arm_group_label>Group 2: Potential liver donor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: Patients who will undergo hepatic resection/RFA for HCC. Group 2: Potential liver&#xD;
        donors with normal hepatic function.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with the diagnosis of HCC based on noninvasive diagnostic criteria of HCC&#xD;
             proposed by 2010 AASLD&#xD;
&#xD;
          2. Surgical resection of hepatic resection greater than 2 Couinaud segments (including&#xD;
             total hepatectomy for transplantation) or radiofrequency ablation is planned&#xD;
&#xD;
          3. Patients who provided the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 yrs old&#xD;
&#xD;
          2. Patients who received hepatic surgery prior to this study&#xD;
&#xD;
          3. Patients who underwent TACE or RFA for greater than 2 segments within 3 months prior&#xD;
             to this study&#xD;
&#xD;
          4. Patients who received radiation treatment including the liver or systemic chemotherapy&#xD;
&#xD;
          5. Patients who underwent contrast enhanced liver MRI within 3 days prior to this study&#xD;
&#xD;
          6. Patients with severe renal dysfunction (Cr .2.5 mg/dL or GFR &lt; 30mL/min)&#xD;
&#xD;
          7. Patients with hypersensitivity to gadolinium&#xD;
&#xD;
          8. Patients with uncorrectable hypokalemia&#xD;
&#xD;
          9. Pregnant women, or reproductive age women who will not agree with contraception during&#xD;
             this study period.&#xD;
&#xD;
         10. Patients with mental disorder which will interfere with voluntary agreement&#xD;
&#xD;
         11. Patients who have any contraindication to MRI (cardiac pacemaker, ferromagnetic&#xD;
             implants, etc.)&#xD;
&#xD;
         12. Any other condition which, in the opinion of the Investigator, would make the patient&#xD;
             unsuitable for enrollment or could interfere with the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cheonnam University Hwasun Hospital</name>
      <address>
        <city>Hwasun-Gun</city>
        <state>Cheonnam Province</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gd-EOB-DTPA</keyword>
  <keyword>MRI</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Liver Function Tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

